EarningsQ3 FY2026 · reported Nov 5, 2026
Cigna beat by 6.1% on adjusted EPS.
$7.98 a share against a $7.52 consensus. Revenue $73.7B against $72.6B, in line.
EPS
Revenue
Beat 5In line 1
Next report Feb 4, 2027. Consensus $7.19 a share.
Every quarter
Insider and Congress filings
Healthcare Plans, listed on NYSE.
S&P 500 · 338 insider transactions · 137 Congress trades · last filed Oct 7, 2026
Free on iOS and Android
Email me new Cigna filings
FREE. An email on days Cigna insiders file a trade or Cigna reports results. One a day at most.
Check your inbox
We sent a link to your address. Tap it to confirm; we email nothing until you do.
Want it the moment it is filed? The app sends a push, free.
EarningsQ3 FY2026 · reported Nov 5, 2026
Cigna beat by 6.1% on adjusted EPS.
$7.98 a share against a $7.52 consensus. Revenue $73.7B against $72.6B, in line.
EPS
Revenue
Beat 5 · In line 1
Next report Feb 4, 2027. Consensus $7.19 a share.
Every quarterMoney managers13F filings for Jun 30, 2026
of the 97 fund managers GetSignal tracks list Cigna among their largest positions. Two Sigma held the most, $499.8M.
Insider tradesForm 4 · 5 open-market filings shown
Five open-market sales, 4 of them under 10b5‑1 plans.
May 12, 2026Sep 3, 2026
Sales · Sales under a plan
A median 2 business days from trade to filing. Form 4 is due within two.
Every filingCongressSTOCK Act disclosures to the House and Senate
20 Congress disclosures shown, from 6 members.
6 members of Congress report a position in CI, by our estimate. Who holds it
Every Congress trade in CIEvery disclosure| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q3 FY2026reported Nov 5, 2026 | $7.98 | $7.52 | $73.7B | $72.6B | EPS beatRevenue in line |
| Q2 FY2026reported Jul 30, 2026 | $7.78 | $7.60 | $71.7B | $70.1B | EPS beatRevenue beat |
| Q1 FY2026reported Apr 30, 2026 | $7.79 | $7.60 | $68.5B | $66.3B | EPS beatRevenue beat |
| Q4 FY2025reported Feb 5, 2026 | $8.08 | $7.88 | $72.5B | $70.3B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 30, 2025 | $7.83 | $7.64 | $69.7B | $67.6B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 31, 2025 | $7.20 | $7.16 | $67.2B | $62.9B | EPS in lineRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
No earnings call briefs on CI yet. Briefs from every company we cover.
Past year Each firm's latest target, newest first
| Firm | Rating | Target | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Equal Weightrated Jul 31, 2026 | $325 | Raised from $307 | |
| Bernstein | Outperform | $390 | Raised from $387 | |
| Piper Sandler | Overweight | $370 | Target set | |
| Jefferies | Hold | $307 | Target set | |
| Raymond James | Outperform | $320 | Target set | |
| Baird | Not stated | $362 | Raised from $337 | |
| Guggenheim | Buy | $361 | Target set | |
| Wolfe Research | Not stated | $315 | Target set | |
| Mizuho | Outperform | $340 | Raised from $330 | |
| Barclays | Equal Weight | $304 | Target set | |
| UBS | Buy | $400 | Raised from $375 | |
| Morgan Stanley | Overweight | $361 | Raised from $355 | |
| Deutsche Bank | Hold | $302 | Target set | |
| Cantor Fitzgerald | Overweight | $340 | Target set | |
| Truist Securities | Buy | $350 | Raised from $320 | |
| TD Cowen | Buy | $338 | Raised from $333 |
Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice. A rating with its own date under it is the firm's latest from the past 120 days, where the note stated none.
1 other firm rated CI in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 16, 2026.
| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| David M. CordaniChair and Chief Executive Officer | $1.6M | $13.9M | $7.3M | $22.9M |
| Brian C. EvankoPresident and Chief Operating Officer | $1.1M | $5.1M | $3.9M | $10.0M |
| Nicole S. JonesExecutive Vice President, Chief Administrative Officer, and General Counsel | $893K | $2.9M | $2.1M | $6.0M |
| Ann M. DennisonExecutive Vice President, Chief Financial Officer, The Cigna Group | $773K | $2.3M | $1.6M | $4.7M |
| Everett NevilleExecutive Vice President, Strategy and Business Development | $800K | $1.7M | $1.6M | $4.1M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $6.6B | 24,113,368 | +2.9% | 9.14% |
| Vanguard Capital Management LLC | $4.7B | 17,290,980 | +0.1% | 6.55% |
| State Street Corp | $3.5B | 12,959,550 | +2.2% | 4.91% |
| Dodge & Cox | $3.3B | 12,255,467 | +0.7% | 4.64% |
| Sanders Capital, LLC | $2.7B | 10,098,076 | -0.5% | 3.83% |
| Massachusetts Financial Services Co | $2.7B | 9,740,280 | -6.7% | 3.69% |
| FMR LLC | $1.9B | 6,813,015 | -15.0% | 2.58% |
| Geode Capital Management, LLC | $1.8B | 6,817,241 | +8.8% | 2.58% |
| Vanguard Portfolio Management LLC | $1.7B | 6,307,222 | +1.3% | 2.39% |
| JPMorgan Chase & Co. | $1.4B | 5,051,747 | -2.7% | 1.91% |
| Morgan Stanley | $1.0B | 3,745,005 | +1.5% | 1.42% |
| Arrowstreet Capital, Limited Partnership | $757.4M | 2,786,463 | -2.2% | 1.06% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Two Sigma | $499.8M | 1,813,110 | 0.4% |
| Glenview CapitalLarry Robbins | $113.6M | 412,223 | 2.1% |
| Leon CoopermanOmega Advisors | $89.6M | 325,000 | 2.5% |
| David EinhornGreenlight Capital | $24.4M | 88,400 | 0.6% |
4 of the 97 fund managers we track list CI shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Everett Neville | Sold · scheduled | 617 | $284.05 | $175K | Sep 3, 2026filed Sep 8, 2026 | 2d |
| Nicole S. Jones | Sold · scheduled | 2,677 | $279.61 | $749K | Aug 18, 2026filed Aug 20, 2026 | 2d |
| Nicole S. Jones | Sold · scheduled | 19,436 | $276.27 | $5.4M | Aug 4, 2026filed Aug 6, 2026 | 2d |
| Jamie G. KatesChief Accounting Officer | Sold | 899 | $298.61 | $268K | Jun 12, 2026filed Jun 16, 2026 | 2d |
| David CordaniChairman & CEO | Sold · scheduled · 13 lines | 201,878 | $292.82 | $59.1M | May 12, 2026filed May 14, 2026 | 2d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
| Insider | Event | Shares | Date |
|---|---|---|---|
| Brian C. Evanko | Stock award | 9,829 | Sep 1, 2026 |
| George KurianDirector | Stock award | 109 | Aug 31, 2026 |
| Bryan Holgerson | Stock award | 0.887 | Jul 9, 2026 |
| Bryan Holgerson | Stock award | 0.946 | Jul 23, 2026 |
| Bryan Holgerson | Stock award | 0.984 | Aug 6, 2026 |
| Nicole S. Jones | Option exercise | 1,301 | Aug 5, 2026 |
| Nicole S. Jones | Option exercise | 14,045 | Aug 4, 2026 |
| Matthew Perlberg | Other Form 4 entry (see filing) | 6,343 | Mar 1, 2026 |
| Matthew Perlberg | Other Form 4 entry (see filing) | 5,658 | Mar 1, 2025 |
| Matthew Perlberg | Other Form 4 entry (see filing) | 791 | Mar 1, 2023 |
| Matthew Perlberg | Other Form 4 entry (see filing) | 3,136 | Mar 1, 2024 |
| Jason D. Sadler | Other Form 4 entry (see filing) | 5,791 | Mar 1, 2026 |
| Jason D. Sadler | Other Form 4 entry (see filing) | 6,257 | Mar 1, 2024 |
| Jason D. Sadler | Other Form 4 entry (see filing) | 5,400 | Mar 1, 2025 |
| Adam Kautzner | Other Form 4 entry (see filing) | 8,708 | Mar 1, 2026 |
| Adam Kautzner | Other Form 4 entry (see filing) | 5,955 | Mar 1, 2025 |
| Adam Kautzner | Other Form 4 entry (see filing) | 3,764 | Mar 1, 2024 |
| Adam Kautzner | Other Form 4 entry (see filing) | 1,778 | Mar 1, 2023 |
| Adam Kautzner | Other Form 4 entry (see filing) | 2,008 | Mar 1, 2022 |
| Adam Kautzner | Other Form 4 entry (see filing) | 1,579 | Feb 26, 2021 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Stock | Sale | $1,001 - $15,000 | +9.2% since the saleEstimated exit price $272.01, close on Fri Sep 25Current price $297.00, close on Fri Nov 13 | Sep 25, 2026 | Oct 7, 2026 | 12d | |
| Stock | Sale | $1,001 - $15,000 | +4.6% since the saleEstimated exit price $283.94, close on Mon Jul 20Current price $297.00, close on Fri Nov 13 | Jul 20, 2026 | Aug 7, 2026 | 18d | |
| Stock | Sale | $1,001 - $15,000 | +2.4% since the saleEstimated exit price $290.08, close on Tue Sep 23, 2025Current price $297.00, close on Fri Nov 13 | Sep 23, 2025 | Aug 5, 2026 | 316d | |
| Stock | Purchase | $1,001 - $15,000 | +2.4% since the tradeEstimated entry price $290.08, close on Tue Sep 23, 2025Current price $297.00, close on Fri Nov 13 | Sep 23, 2025 | Aug 5, 2026 | 316d | |
| Stock | Purchase | $1,001 - $15,000 | +13.4% since the tradeEstimated entry price $261.96, close on Fri Mar 27Current price $297.00, close on Fri Nov 13 | Mar 27, 2026 | Jul 21, 2026 | 116d | |
| Stock | Sale | $15,001 - $50,000 | +8.9% since the saleEstimated exit price $272.72, close on Tue Jun 2Current price $297.00, close on Fri Nov 13 | Jun 2, 2026 | Jul 6, 2026 | 34d | |
| Stock | Purchase | $1,001 - $15,000 | +4.1% since the tradeEstimated entry price $285.27, close on Fri May 15Current price $297.00, close on Fri Nov 13 | May 15, 2026 | Jun 9, 2026 | 25d | |
| Stock | Sale | $1,001 - $15,000 | +7.7% since the saleEstimated exit price $275.64, close on Fri Apr 24Current price $297.00, close on Fri Nov 13 | Apr 24, 2026 | May 11, 2026 | 17d | |
| Stock | Sale | $15,001 - $50,000 | +8.0% since the saleEstimated exit price $275.12, close on Mon Apr 13Current price $297.00, close on Fri Nov 13 | Apr 13, 2026 | May 11, 2026 | 28d | |
| Stock | Sale | $1,001 - $15,000 | +13.6% since the saleEstimated exit price $261.49, close on Mon Mar 23Current price $297.00, close on Fri Nov 13 | Mar 23, 2026 | Apr 30, 2026 | 38d | |
| Stock | Sale | $1,001 - $15,000 | +11.2% since the saleEstimated exit price $267.19, close on Fri Mar 13Current price $297.00, close on Fri Nov 13 | Mar 13, 2026 | Apr 7, 2026 | 25d | |
| Stock | Purchase | $1,001 - $15,000 | +2.2% since the tradeEstimated entry price $290.71, close on Tue Feb 17Current price $297.00, close on Fri Nov 13 | Feb 17, 2026 | Mar 9, 2026 | 20d | |
| Stock | Purchase | $1,001 - $15,000 | +5.7% since the tradeEstimated entry price $281.00, close on Tue Feb 24Current price $297.00, close on Fri Nov 13 | Feb 24, 2026 | Mar 9, 2026 | 13d | |
| Stock | Purchase | $1,001 - $15,000 | +9.3% since the tradeEstimated entry price $271.81, close on Tue Jan 13Current price $297.00, close on Fri Nov 13 | Jan 13, 2026 | Feb 6, 2026 | 24d | |
| Stock | Purchase | $15,001 - $50,000 | +9.5% since the tradeEstimated entry price $271.27, close on Thu Jan 29Current price $297.00, close on Fri Nov 13 | Jan 29, 2026 | Feb 6, 2026 | 8d | |
| Stock | Sale | $1,001 - $15,000 | +8.4% since the saleEstimated exit price $274.00, close on Thu Dec 18, 2025Current price $297.00, close on Fri Nov 13 | Dec 18, 2025 | Jan 15, 2026 | 28d | |
| Stock | Purchase | $1,001 - $15,000 | -6.5% since the tradeEstimated entry price $317.57, close on Wed Oct 23, 2024Current price $297.00, close on Fri Nov 13 | Oct 23, 2024 | Jan 13, 2026 | 447d | |
| Stock | Sale | $1,001 - $15,000 | -11.9% since the saleEstimated exit price $337.07, close on Tue Apr 22, 2025Current price $297.00, close on Fri Nov 13 | Apr 22, 2025 | Jan 13, 2026 | 266d | |
| Stock | Purchase | $1,001 - $15,000 | +9.2% since the tradeEstimated entry price $271.89, close on Fri Dec 19, 2025Current price $297.00, close on Fri Nov 13 | Dec 19, 2025 | Jan 12, 2026 | 24d | |
| Stock | Sale | $1,001 - $15,000 | +9.8% since the saleEstimated exit price $270.61, close on Wed Nov 12, 2025Current price $297.00, close on Fri Nov 13 | Nov 12, 2025 | Dec 15, 2025 | 33d |
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in CI filterable by party, chamber, type and account.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Republican · House | $50,001 - $100,000 | 0.5% | |
| Democrat · House | $50,001 - $100,000 | 0.8% | |
| Republican · House | $15,001 - $50,000 | 1.3% | |
| Republican · House | $15,001 - $50,000 | 0.1% | |
| Democrat · House | $1,001 - $15,000 | 7.3% | |
| Republican · House | $1,001 - $15,000 | 1.0% |
The largest estimated position is in the $50,001 - $100,000 band. Estimate, as of Nov 14, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
Data as of Nov 16, 2026.
What the filings on CI show and how current they are.
Across the 5 most recent open-market filings shown here, 0 were purchases and 5 were sales. 4 were scheduled in advance under a Rule 10b5-1 plan.
Ro Khanna, Julie Johnson, Alan Armstrong, Jared Moskowitz, Gilbert Ray Cisneros, Jr. and Julia Letlow disclosed CI transactions in the filings shown here.
6 members of Congress report a position in CI in the estimate we hold as of Nov 14, 2026. The two largest estimated positions belong to J. French Hill and Lucy McBath; Mark Harris holds one of the next largest, in the $15,001 - $50,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Cigna Corporation is a current member of the S&P 500, per the membership list we hold as of Nov 16, 2026. Current members of either index get a page here whatever their filing history.
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 27 days, against the 45 the STOCK Act allows.